Initial evidence suggests that targeting the innate immunity pathway through IL-1β inhibition with canakinumab could significantly reduce incident lung cancer and lung cancer mortality in patients treated for atherosclerosis [6]. The gene discussed is IL1B; the disease is lung cancer.